Product
Safer and higher quality with AI technology
The radiotherapy AI "AIVOT" that we are developing is AI that learns high-quality data from High-volume center in Japan, and solves problems by automating various processes in intensity-modulated radiation therapy (IMRT).
AIVOT-QA
AIVOT-QA, which aims to perform the QA of the quality and safety of radiotherapy plans,
will be on sale from April 2023. This is software with limited functions of radiation therapy support software (AIVOT), which is under development as a pharmaceutical approved medical device.
■ Feature
1. Function of treatment plan QA
- By setting a target and OAR in AI, the AI learned from high volume center data in Japan will display a model dose distribution in about 2 minutes.
- Compatible with domestic and international clinical trial protocols such as JCOG※ and RTOG※JCOG1408, JCOG1912
2. Function of virtual patient-specific QA
- By inputting treatment plan data, the software outputs high-quality safety results (predict gamma pass rate) with its own AI technology.
- A treatment plan complexity index (such as MCSv) can also be calculated.
■ Treatment site
◆Function of treatment plan QA- prostate cancer, head and neck cancer, early stage lung cancer (SRT), advanced-stage lung cancer (StageIII), cervical cancer
- prostate cancer, head and neck cancer, early stage lung cancer (SRT), advanced-stage lung cancer (StageIII)
■ Treatment technique
- VMAT
■Enabled TPS
- conventional TPS (Eclipse*1, Monaco*2, RayStation*3etc）
■Enabled Linac
- C-arm Linac (TrueBeam*1, VersaHD*2etc）
*1:Eclipse, TrueBeam is a trademark of Varian Medical Systems Inc.
*2:Monaco, VersaHD is a trademark of Elekta AB(publ)
*3:RayStation is a trademark of RaySearch Laboratories AB
*2:Monaco, VersaHD is a trademark of Elekta AB(publ)
*3:RayStation is a trademark of RaySearch Laboratories AB
Under development
AIVOT equipped with the following functions cannot be sold as a medical device. However, it can be sold for educational and research purposes. Since it is possible to request an estimate and demo at any time, we would appreciate it if you could request it from the inquiry form.
※We are also looking for sites for joint research (test evaluation, etc.).
※We are also looking for sites for joint research (test evaluation, etc.).
AI-based automatic contouring
- This function can automatically generate the contour of normal tissue by inputting a CT image. Our unique AI technology enables highly accurate automatic contour extraction.
- Enabled treatment site: head and neck, thorax, pelvic
AI based automatic planning
- By inputting CT images and tumor/normal tissue contours, this function can generate high-quality treatment plans using proprietary AI technology.
- Enabled treatment site: prostate cancer, head and neck cancer (2 step, SIB),early stage lung cancer (SRT), advanced-stage lung cancer (StageIII), cervical cancer
- treatment technique: VMAT
- Development stage: Prototype completed (May 2023), evaluation stage at test site
Inquiries, other
Since it is possible to request an estimate and demo at any time, we would appreciate it if you could request it from the inquiry form.
● Specifications are subject to change without notice due to improvements, etc.
● The displayed screen image may differ from the actual screen color tone.
● All company names and product names mentioned are trademarks or registered trademarks of their respective companies.
● Specifications are subject to change without notice due to improvements, etc.
● The displayed screen image may differ from the actual screen color tone.
● All company names and product names mentioned are trademarks or registered trademarks of their respective companies.
Technology Topic
Contact
[For medical professionals] For inquiries about AIVOT, please contact us from here
[contact-form-7 id="79" title="Technology Contact form 英語用準備"]